Burren Capital Advisors Ltd bought a new stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 23,044 shares of the health services provider's stock, valued at approximately $2,092,000. Amedisys makes up approximately 10.1% of Burren Capital Advisors Ltd's investment portfolio, making the stock its 3rd biggest holding. Burren Capital Advisors Ltd owned approximately 0.07% of Amedisys at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Pacer Advisors Inc. raised its holdings in shares of Amedisys by 11,621.9% during the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider's stock valued at $50,679,000 after purchasing an additional 553,435 shares in the last quarter. Polar Asset Management Partners Inc. bought a new position in Amedisys during the third quarter valued at about $28,953,000. Verition Fund Management LLC lifted its position in shares of Amedisys by 608.1% in the third quarter. Verition Fund Management LLC now owns 114,774 shares of the health services provider's stock worth $11,077,000 after buying an additional 98,565 shares during the last quarter. Westchester Capital Management LLC lifted its position in shares of Amedisys by 9.5% in the third quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider's stock worth $107,976,000 after buying an additional 97,476 shares during the last quarter. Finally, Calamos Advisors LLC boosted its stake in shares of Amedisys by 22.7% during the 4th quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider's stock worth $44,255,000 after acquiring an additional 90,097 shares in the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, Stephens reissued an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $100.75.
View Our Latest Stock Analysis on Amedisys
Amedisys Stock Performance
AMED stock traded up $0.03 during mid-day trading on Wednesday, reaching $92.12. 446,688 shares of the stock traded hands, compared to its average volume of 379,010. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average of $92.06 and a two-hundred day moving average of $92.86. The firm has a market capitalization of $3.02 billion, a PE ratio of 36.56, a P/E/G ratio of 1.78 and a beta of 0.76. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95.
Amedisys (NASDAQ:AMED - Get Free Report) last announced its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The business had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. As a group, equities analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.
Amedisys Company Profile
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Further Reading
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
